Bristol-Myers Squibb Enter Partnership with Tibotec Pharmaceuticals
Bristol-Myers Squibb have entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical Companies, to assess the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, combined with Tibotec Pharmaceuticals’ investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
Within the agreement, the two companies will evaluate the opportunity to achieve sustained viral response within 12 and 24 weeks post-treatment in patients with HCV genotype 1.
The study will consist of three different oral treatment regimens: once-daily treatment regimen of daclatasvir and TMC435 with pegylated-interferon alpha plus ribavirin; once-daily treatment regimen of daclatasvir and TMC435 with ribavirin and once-daily treatment regimen of just daclatasvir and TMC435.
Discovered by Bristol-Myers Squibb through a genomics approach, daclatasvir is the first NS5A replication complex inhibitor to be studied in clinical trials and is currently in Phase III development. Daclatasvir is part of a portfolio of investigational compounds that Bristol-Myers Squibb is developing for the treatment of hepatitis C. The Phase II study is planned for the beginning of next year.
Brian Daniels, senior vice president, Development at B-MS, commented that Bristol-Myers Squibb is dedicated to developing innovative treatment options for patients with serious diseases like HCV.” We are pleased to work with Tibotec to advance the scientific understanding for the potential for an all-oral regimen of direct acting antivirals, which would be an important advancement for patients with HCV. This is a continuation of our leadership in forging partnerships to advance combination antiviral therapy,” he added.